RESEARKA

The geroscience hypothesis posits that fundamental aging processes underlie the pathogenesis of multiple chronic diseases, suggesting that targeting these shared mechanisms could yield broad healthspan benefits. This framework identifies interconnected biological hallmarks—including chronic inflammation, oxidative stress, cellular senescence, and metabolic dysregulation—that collectively drive age-related functional decline and multimorbidity. The proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors longevity) pathway intersects several of these hallmarks, initially characterized for its role in hepatic low-density lipoprotein receptor degradation. Regulatory bodies approved PCSK9 inhibitors longevity primarily for cardiovascular risk reduction in patients with familial hypercholesterolemia or established atherosclerotic disease. However, the broader question of whether sustained LDL-C reduction via this mechanism confers longevity-relevant benefits beyond atherosclerosis remains an active area of investigation, with implications for how lipid-lowering agents might be repurposed within a geroscience-informed therapeutic strategy.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023